How does Creative Biolabs ensure the peptides are tumor-specific, not just highly vascular?

Our screening includes negative selection strategies such as pre-clearing with non-tumor tissues or using control animals. Additionally, comparative enrichment analysis across different tissues helps filter out broadly distributed peptides, enhancing tumor specificity.

Can I request additional validation beyond ligand identification?

Yes. Creative Biolabs offers downstream services including labeled peptide synthesis, binding assays, and in vivo imaging to confirm peptide localization in tumors. These can be added at any point post-screening.

What kind of phage library do you use?

We use high-complexity random peptide libraries, or you may supply your own. We ensure high diversity and reproducibility throughout the process.

How many animals are typically used in a project?

A standard screen involves 3–6 tumor-bearing animals per enrichment round, with additional control animals if required. Larger cohorts may be used for validation phases.

Can I customize the route of phage administration?

Absolutely. We offer intravenous, intraperitoneal, and intratumoral injections depending on your tumor type, accessibility, and targeting goals.

Tumor Targeting In Vivo Phage Library Screening Service

Introduction Our Services Workflow Platform Advantages Deliverables FAQ Resources

Pioneering Targeted Cancer Therapy with In Vivo Phage Display

The complexity and heterogeneity of tumor microenvironments present major challenges to the development of precise cancer-targeting therapies and diagnostics. At Creative Biolabs, we harness the power of in vivo phage display to overcome these challenges, enabling the identification of peptides that home selectively to tumor tissues in living models. Unlike in vitro methods that often fail to replicate the real-time biodistribution and cellular interactions of tumor biology, our approach ensures that only biologically viable and functionally relevant candidates are selected.

With extensive expertise in oncology-targeted molecular screening, Creative Biolabs offers specialized services designed to support preclinical therapeutic design, companion diagnostics, and tumor-targeted delivery vehicles. We help you identify what works—not just in theory, but in the living system.

What We Offer: Tumor-Selective Peptide Discovery

Our tumor-targeting in vivo phage library screening services are designed for researchers pursuing specific tumor tropism in the following applications:

Identifying ligands that bind preferentially to solid tumors (e.g., breast, lung, colorectal, glioma)
Discovering peptides that differentiate between malignant and adjacent normal tissue
Enabling the targeted delivery of therapeutics (e.g., nanoparticle/drug conjugates)
Supporting tumor imaging and diagnostic development via peptide probes
Mapping tumor heterogeneity and vascular accessibility through ligand profiling

Each screening campaign is fully customizable based on tumor type, xenograft model, administration route (i.v., i.p., etc.), and downstream goals such as therapeutic targeting or biomarker discovery. We'd be happy to discuss customized solutions tailored to your needs.

Step-by-Step: From Library to Ligand

Our refined workflow includes:

Consultation & Experimental Design

Creative Biolabs scientists collaborate closely with you to define the tumor type, model system, and screening objectives. Depending on the study goals, we help determine whether to use human or mouse xenografts, and whether orthotopic or subcutaneous implantation best suits your research. This planning stage ensures experimental conditions align with biological relevance and downstream validation needs.
Phage Library Administration

A high-diversity phage display library containing more than 10⁹ unique clones is selected or custom-constructed for your project. The library is systemically administered into tumor-bearing animals via intravenous injection under defined dosing conditions. This diversity enables broad coverage of potential tumor-targeting peptides.
Systemic Circulation & Homing Phase

Following injection, the phage particles circulate through the bloodstream, interacting with vascular and tumor microenvironments. Phages that recognize tumor-associated receptors or extracellular matrix components preferentially accumulate in the tumor site. Circulation time and collection endpoints are carefully optimized to balance biodistribution and specific targeting.
Tissue Harvesting & Target Enrichment

Tumor tissues are precisely dissected after circulation to recover phages that have bound to or penetrated the tumor microenvironment. Stringent washing steps remove non-specifically bound phages, and recovered populations are amplified for subsequent rounds of selection. Multiple enrichment cycles progressively refine the library toward clones with strong tumor affinity and selectivity.
Sequencing & Bioinformatics

Enriched phage populations are analyzed through next-generation sequencing (NGS) or Sanger sequencing to identify dominant peptide sequences. Bioinformatics pipelines cluster sequences, detect motif enrichment, and highlight consensus patterns correlated with tumor binding. The resulting data reveal candidate peptides with potential diagnostic, imaging, or therapeutic utility.
Validation (Optional)

Top candidate peptides can be synthesized or displayed for in vitro binding and cell-based assays to confirm tumor selectivity. In vivo validation may include imaging of labeled peptides in animal models or functional testing to assess tumor uptake and retention. This step provides proof-of-concept for translational applications such as targeted drug delivery or molecular imaging.

For a personalized quote, please reach out to us.

Our Technology Advantage: Beyond Static Screens

Creative Biolabs' tumor-targeting phage display platform is engineered to replicate real-life complexity. It doesn't stop at affinity—it also evaluates biodistribution, tumor penetration, and interaction with the tumor stroma and vasculature.

This comprehensive screening framework is capable of accommodating libraries of over a billion unique clones per experiment, maximizing the chance of discovering unique, disease-relevant ligands. Importantly, our in vivo screen respects physiological barriers such as immune clearance, non-specific retention, and metabolic breakdown—ensuring that the identified ligands are not only selective but stable and deliverable.

Why Partner with Creative Biolabs?

Biological Relevance

Our screens occur in live models, not petri dishes—capturing the true behavior of peptide candidates under physiological conditions.

Tailored Experimental Design

Every project is customized to your tumor model, research objectives, and preferred analysis method.

Unparalleled Diversity

Libraries containing >10⁹ clones increase the probability of discovering novel tumor-specific ligands.

Data-Driven Discovery

Integration of sequencing, statistical enrichment analysis, and motif clustering ensures you receive results that are actionable, not just descriptive.

If you're interested in tailored solutions, don't hesitate to get in touch.

What You Receive

At the completion of your tumor-targeting in vivo phage display campaign, Creative Biolabs provides a comprehensive data and materials package designed to support both immediate follow-up experiments and long-term translational goals. You will receive:

Detailed Experimental Report
Including animal model used, tumor type and location, phage administration route, circulation time, tissue collection protocols, and number of enrichment rounds.
Sequence Data
NGS or Sanger sequencing results for enriched phage clones, with raw data and clean FASTA files provided for your own bioinformatics use.
Clonal Enrichment Analysis
Statistical analysis showing the most enriched peptide sequences, with frequency plots, heatmaps, and motif clustering for candidate prioritization.
Custom Peptide Synthesis (Optional)
Creative Biolabs can synthesize your top hit peptides with tags or modifications for downstream imaging, binding, or functional studies.
Peptide Validation Services (Optional)
For select projects, we offer validation of ligand binding via ELISA, tissue binding assays, or in vivo imaging using fluorescently labeled peptides.
Phage Clone Archiving
Purified top clones can be returned upon request or stored at Creative Biolabs for future use.

Follow-up consultation with Creative Biolabs scientists is included to help interpret the results and plan your next steps. Let Creative Biolabs help you uncover peptides that make a difference—in the lab and beyond. Reach out today for a custom quote or free consultation with one of our scientists.

Frequently Asked Questions

How does Creative Biolabs ensure the peptides are tumor-specific, not just highly vascular?
A: Our screening includes negative selection strategies such as pre-clearing with non-tumor tissues or using control animals. Additionally, comparative enrichment analysis across different tissues helps filter out broadly distributed peptides, enhancing tumor specificity.
Can I request additional validation beyond ligand identification?
A: Yes. Creative Biolabs offers downstream services including labeled peptide synthesis, binding assays, and in vivo imaging to confirm peptide localization in tumors. These can be added at any point post-screening.
What kind of phage library do you use?
A: We use high-complexity random peptide libraries, or you may supply your own. We ensure high diversity and reproducibility throughout the process.
How many animals are typically used in a project?
A: A standard screen involves 3–6 tumor-bearing animals per enrichment round, with additional control animals if required. Larger cohorts may be used for validation phases.
Can I customize the route of phage administration?
A: Absolutely. We offer intravenous, intraperitoneal, and intratumoral injections depending on your tumor type, accessibility, and targeting goals.